Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
shugan jieyu + escitalopram
- Development stage
- Unknown
- Lead developer
- Chengdu Kanghong Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Shugan Jieyu + escitalopram is a combination therapy consisting of the Traditional Chinese Medicine (TCM) Shugan Jieyu capsule and the selective serotonin reuptake inhibitor (SSRI) escitalopram. Shugan Jieyu is a standardized herbal formulation primarily composed of *Hypericum perforatum* (St. John's Wort) and *Acanthopanax senticosus* (Siberian ginseng), which is widely used in China for mild-to-moderate depression. Escitalopram is a potent SSRI that selectively inhibits the serotonin transporter (SERT). This combination is frequently utilized in clinical practice and research in China, such as studies conducted by the Shandong Mental Health Center, to achieve a faster onset of antidepressant action, improve response rates in patients with Major Depressive Disorder, and potentially mitigate the side effects associated with high-dose SSRI monotherapy.
- Brand names
- Cipralex
- Other names
- Shugan Jieyu capsule plus escitalopramShugan Jieyu combined with escitalopramShugan Jieyu and escitalopram oxalate
02
Targets
SERT (Sodium-dependent serotonin transporter)NET (Norepinephrine Transporter)DAT (Dopamine plasma membrane transport protein)MAOA (Monoamine oxidase A)
Beyond the preview
Go deeper on shugan jieyu + escitalopram.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on shugan jieyu + escitalopram.